Moberg Derma Obtains Approval For Novel Treatment For Nail Diseases

Published: Apr 13, 2010

Moberg Derma AB today announced that CE-mark has been granted for the company’s first approved medical device product, used for the treatment of discolored and damaged nails, for example caused by nail fungus (onycomycosis) or nail psoriasis. The CE mark provides authorization to market and sell the product in the EU/EEA.

“The approval is a result of focused development work during several years and is an important milestone for Moberg Derma. We now look forward to launch the product in close cooperation with our partners in the first markets” says Moberg Derma's President and CEO, Peter Wolpert.

About the product and nail fungus (onychomycosis)

Moberg’s topical nail product is prescription free and has the potential to become first-line treatment for common nail disorders. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. The product has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment.

Nail fungus is the most common nail disease and afflicts approximately 10% of the general population. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

Contact Moberg Derma

Peter Wolpert, President and CEO

Telephone: +46 8 - 522 307 00

Mobile: +46 70 - 735 71 35


About Moberg Derma

Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain marketing rights. The company began operations at the Karolinska Institute in 2006. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit:

Back to news